Literature DB >> 18042329

Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: is there a link?

Konstantinos Hatzimouratidis1.   

Abstract

Nonarteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy and one of the most common causes of sudden vision loss in the elderly. Recently, NAION has been associated with the use of phosphodiesterase type 5 inhibitors (PDE5i) in men with erectile dysfunction (ED). A causal relationship could not be established given the large number of men safely using PDE5i and the limited number of NAION cases reported in these men. ED and NAION share common risk factors; therefore, some men with ED should be expected to develop NAION. However, sudden vision loss or decreased vision in one or both eyes demands immediate cessation of PDE5i use and urgent patient assessment. No causal relationship between PDE5i and the development of NAION exists for the moment, yet physicians should be aware of a possible adverse reaction and inform patients accordingly.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18042329     DOI: 10.1007/s11934-007-0053-1

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  67 in total

1.  Tadalafil-associated anterior ischaemic optic neuropathy.

Authors:  N M Peter; M V Singh; P D Fox
Journal:  Eye (Lond)       Date:  2005-06       Impact factor: 3.775

2.  Viagra or what?

Authors:  S Sinha; V Pathak-Ray; H Ahluwalia; J E Morgan
Journal:  Eye (Lond)       Date:  2004-04       Impact factor: 3.775

3.  Effect of sildenafil citrate (Viagra) on retinal blood vessel diameter.

Authors:  Juan E Grunwald; Tatyana Metelitsina; Lili Grunwald
Journal:  Am J Ophthalmol       Date:  2002-06       Impact factor: 5.258

4.  Sildenafil causes a dose- and time-dependent downregulation of phosphodiesterase type 6 expression in the rat retina.

Authors:  C M Gonzalez; T Bervig; C Podlasek; C F Huang; K E McKenna; K T McVary
Journal:  Int J Impot Res       Date:  1999-09       Impact factor: 2.896

Review 5.  Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient.

Authors:  Piero Montorsi; Paolo M Ravagnani; Stefano Galli; Andrea Salonia; Alberto Briganti; José P Werba; Francesco Montorsi
Journal:  Eur Urol       Date:  2006-07-28       Impact factor: 20.096

6.  Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.

Authors:  Curtis E Margo; Dustin D French
Journal:  Am J Ophthalmol       Date:  2006-11-13       Impact factor: 5.258

7.  Ischemic optic neuropathy as the first manifestation of elevated cholesterol levels in young patients.

Authors:  Vincent A Deramo; Robert C Sergott; James J Augsburger; Rod Foroozan; Peter J Savino; Anthony Leone
Journal:  Ophthalmology       Date:  2003-05       Impact factor: 12.079

8.  A case of nonarteritic ischemic optic neuropathy (NAION) in a male patient taking sildenafil.

Authors:  A Boshier; N Pambakian; S A W Shakir
Journal:  Int J Clin Pharmacol Ther       Date:  2002-09       Impact factor: 1.366

9.  Evaluation of optic nerve head configuration in various types of optic neuropathy with Heidelberg Retina Tomograph.

Authors:  A Nagai-Kusuhara; M Nakamura; A Kanamori; Y Nakanishi; S Kusuhara; Akira Negi
Journal:  Eye (Lond)       Date:  2007-05-25       Impact factor: 3.775

10.  Elevated plasma levels of interleukin 8 in patients with acute anterior ischaemic optic neuropathy.

Authors:  N Goldenberg-Cohen; M Kramer; I Bahar; Y Monselise; D Weinberger
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

View more
  2 in total

1.  Unilateral transient cyanopsia as an early symptom of compressive optic neuropathy.

Authors:  Hee Kyung Yang; Jeong-Min Hwang
Journal:  Neurol Sci       Date:  2018-08-24       Impact factor: 3.307

2.  Sildenafil attenuates vaso-obliteration and neovascularization in a mouse model of retinopathy of prematurity.

Authors:  Amani A Fawzi; Jonathan C Chou; Gina A Kim; Stuart D Rollins; Joann M Taylor; Kathryn N Farrow
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-10       Impact factor: 4.799

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.